| SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION |
| NOTE 10:- |
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION
|
| |
|
December 31,
|
|
| |
|
2016
|
|
|
2017
|
|
| |
|
|
|
|
|
|
|
Director fees
|
|
$
|
21
|
|
|
$
|
48
|
|
|
Trade payables
|
|
|
20
|
|
|
|
61
|
|
|
Accrued expenses and other
|
|
|
196
|
|
|
|
200
|
|
| |
|
|
|
|
|
|
|
|
| |
|
$
|
237
|
|
|
$
|
309
|
|
|
b. |
Financial expenses, net
|
| |
|
Year ended
December 31,
|
|
| |
|
2015
|
|
|
2016
|
|
|
2017
|
|
| |
|
|
|
|
|
|
|
|
|
|
Financial expenses:
|
|
|
|
|
|
|
|
|
|
|
Loss from change in fair value of investment in BioCancell and sale of BioCancell shares
|
|
$
|
(36
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
Other
|
|
|
(2
|
)
|
|
|
(15
|
)
|
|
|
(3
|
)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
(38
|
)
|
|
|
(15
|
)
|
|
|
(3
|
)
|
|
Financial income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from the sale of Biocancell shares
|
|
|
-
|
|
|
|
-
|
|
|
|
35
|
|
|
Other
|
|
|
9
|
|
|
|
12
|
|
|
|
13
|
|
| |
|
|
9
|
|
|
|
12
|
|
|
|
48
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$
|
(29
|
)
|
|
$
|
(3
|
)
|
|
$
|
45 |
|